NO125455B - - Google Patents
Download PDFInfo
- Publication number
- NO125455B NO125455B NO1734/68A NO173468A NO125455B NO 125455 B NO125455 B NO 125455B NO 1734/68 A NO1734/68 A NO 1734/68A NO 173468 A NO173468 A NO 173468A NO 125455 B NO125455 B NO 125455B
- Authority
- NO
- Norway
- Prior art keywords
- tetanus
- toxoid
- tetanus toxoid
- pepsin
- product
- Prior art date
Links
- 229960000814 tetanus toxoid Drugs 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 102000057297 Pepsin A Human genes 0.000 description 10
- 108090000284 Pepsin A Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229940111202 pepsin Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010043376 Tetanus Diseases 0.000 description 6
- 229960002766 tetanus vaccines Drugs 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1967B0092391 DE1617344B2 (de) | 1967-05-06 | 1967-05-06 | Verfahren zur herstellung eines tetanus-impfstoffes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO125455B true NO125455B (xx) | 1972-09-11 |
Family
ID=6986370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1734/68A NO125455B (xx) | 1967-05-06 | 1968-05-03 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3542920A (xx) |
| AT (1) | AT277460B (xx) |
| BE (1) | BE714696A (xx) |
| CH (1) | CH513653A (xx) |
| DE (1) | DE1617344B2 (xx) |
| DK (1) | DK119939B (xx) |
| ES (1) | ES353533A1 (xx) |
| FI (1) | FI45765C (xx) |
| FR (1) | FR7913M (xx) |
| GB (1) | GB1229988A (xx) |
| IE (1) | IE32044B1 (xx) |
| IL (1) | IL29925A (xx) |
| LU (1) | LU56019A1 (xx) |
| NL (1) | NL157803B (xx) |
| NO (1) | NO125455B (xx) |
| SE (1) | SE341984B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2340911A1 (de) * | 1973-08-13 | 1975-05-07 | Behringwerke Ag | Tetanus-antigen und verfahren zu seiner herstellung |
| DE2355094C3 (de) * | 1973-11-03 | 1979-05-23 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tetanus-Impfstoffs |
| DE2510987C2 (de) * | 1974-10-29 | 1983-03-24 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tetanusimpfstoffes |
| DE2457047C3 (de) * | 1974-12-03 | 1979-10-31 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe |
| EP0593176A3 (en) * | 1992-09-28 | 1995-03-01 | Wisconsin Alumni Res Found | Pharmaceutical compositions containing botulinum toxin and method of manufacture. |
-
1967
- 1967-05-06 DE DE1967B0092391 patent/DE1617344B2/de active Granted
-
1968
- 1968-04-30 IE IE505/68A patent/IE32044B1/xx unknown
- 1968-04-30 US US725525A patent/US3542920A/en not_active Expired - Lifetime
- 1968-04-30 FI FI681232A patent/FI45765C/fi active
- 1968-05-01 NL NL6806143.A patent/NL157803B/xx not_active IP Right Cessation
- 1968-05-03 CH CH656568A patent/CH513653A/de not_active IP Right Cessation
- 1968-05-03 NO NO1734/68A patent/NO125455B/no unknown
- 1968-05-03 LU LU56019D patent/LU56019A1/xx unknown
- 1968-05-03 DK DK206668AA patent/DK119939B/da unknown
- 1968-05-03 AT AT428068A patent/AT277460B/de not_active IP Right Cessation
- 1968-05-03 IL IL29925A patent/IL29925A/en unknown
- 1968-05-06 SE SE6050/68A patent/SE341984B/xx unknown
- 1968-05-06 BE BE714696D patent/BE714696A/xx unknown
- 1968-05-06 GB GB1229988D patent/GB1229988A/en not_active Expired
- 1968-08-05 FR FR161922A patent/FR7913M/fr not_active Expired
-
1969
- 1969-05-04 ES ES353533A patent/ES353533A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES353533A1 (es) | 1970-01-16 |
| DE1617344B2 (de) | 1976-04-08 |
| US3542920A (en) | 1970-11-24 |
| IE32044B1 (en) | 1973-03-21 |
| CH513653A (de) | 1971-10-15 |
| NL6806143A (xx) | 1968-11-07 |
| LU56019A1 (xx) | 1970-01-13 |
| GB1229988A (xx) | 1971-04-28 |
| BE714696A (xx) | 1968-11-06 |
| FI45765C (fi) | 1972-09-11 |
| SE341984B (xx) | 1972-01-24 |
| IL29925A (en) | 1972-05-30 |
| IE32044L (en) | 1968-11-06 |
| NL157803B (nl) | 1978-09-15 |
| FI45765B (xx) | 1972-05-31 |
| DE1617344A1 (de) | 1971-03-25 |
| FR7913M (xx) | 1970-05-11 |
| IL29925A0 (en) | 1968-07-25 |
| AT277460B (de) | 1969-12-29 |
| DK119939B (da) | 1971-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4459286A (en) | Coupled H. influenzae type B vaccine | |
| Lancefield et al. | Type-specific polysaccharide antigens of group B streptococci | |
| Beachey et al. | Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen | |
| Morse | Isolation and properties of a surface antigen of Staphylococcus aureus | |
| Jansen | The toxic antigenic factors produced by Clostridium botulinum types C and D | |
| US4207414A (en) | Polysaccharide antigens | |
| US4324887A (en) | Type II group B Streptococci polysaccharide | |
| Moran et al. | Chemical Modification of Crude Timothy Grass Pollen Extract: I. Antigenicity and Immunogenicity Changes following Amino Group Modification | |
| NO125455B (xx) | ||
| US3674863A (en) | Polyvalent immunizing agents and methods for their production | |
| US4367222A (en) | Immune globulin specific to Group B streptococci | |
| IE42760B1 (en) | Derivatives of the tetanus toxin, process for their preparation and agents containing them | |
| US4356263A (en) | Method of making a polysaccharide vaccine | |
| Schmidt et al. | Immunodiffusion reactions with rubella antigens | |
| US4367223A (en) | Vaccine against Group B streptococci | |
| US4367221A (en) | Immunization against Group B streptococci | |
| Dubos | The effect of formaldehyde on pneumococci | |
| DK143249B (da) | Fremgangsmaade til fremstilling af en vandig gamma-globulinoploesning til terapeutisk anvendelse mod infektioner af pseudomonas aeruginosa | |
| Yohn et al. | EGHO-4 Viruses: Improved Methods and Strain Selection for Identification and Serodiagnosis | |
| Kane et al. | Existence of multiple immunodeterminants in the type-specific capsular substance of group B type Ia streptococci | |
| Panse et al. | Passive immunity in experimental cholera | |
| US2405740A (en) | Agglutinogen derived from whooping cough organisms | |
| Smadel et al. | INFECTIOUS MYXOMATOSIS OF RABBITS: II. Demonstration of a Second Soluble Antigen Associated with the Disease | |
| Seal et al. | Studies on the purification of alum-precipitated diphtheria toxoid | |
| Keppie et al. | The Chemical Basis of the Virulence of Pasteurella pestis: III. An Immunogenic Product Obtained from Past. pestis which Protects both Guinea-pigs and Mice |